NASDAQ: DRMADermata Therapeutics Inc Stock
$0.35+0.03 (+9.38%)
Updated Apr 22, 2024
DRMA Price
$0.35
Fair Value Price
N/A
Market Cap
$2.34M
52 Week Low
$0.23
52 Week High
$3.68
P/E
-0.13x
P/B
0.37x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.79M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.26
Operating Cash Flow
-$6M
Beta
0.98
Next Earnings
May 16, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DRMA Overview
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company developing and commercializing treatments for medical and aesthetic skin conditions. Its lead candidates are DMT310 and DMT410. Known as Dermata Therapeutics, LLC until 2021, the company was founded in 2014 and is headquartered in San Diego, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DRMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DRMA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DRMA is good value based on its book value relative to its share price (0.37x), compared to the US Biotechnology industry average (5.82x)
P/B vs Industry Valuation
DRMA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DRMA due diligence checks available for Premium users.
Be the first to know about important DRMA news, forecast changes, insider trades & much more!
DRMA News
Valuation
DRMA fair value
Fair Value of DRMA stock based on Discounted Cash Flow (DCF)
Price
$0.35
Fair Value
$9.36
Undervalued by
96.26%
DRMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DRMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.13x
Industry
16.21x
Market
41x
DRMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.37x
Industry
5.82x
DRMA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DRMA's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.1M
Profit Margin
0%
Assets to liabilities
Assets
$8.0M
Liabilities
$1.6M
Debt to equity
0.26
DRMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
$0.0
Financing
$2.0M
DRMA vs Biotech Stocks
Dermata Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.